In the 1990s, the first disease-modifying therapies (DMTs) for multiple sclerosis (MS) were
injectable immunomodulatory (IM) drugs, including four different interferon-β preparations …

It has to be pointed out that these side effects are not to be considered as final and
neurologists should be vigilant against new unknown side effects. The doctor should be …

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis
(PwMS) in France are more than 50 years. This population more than 50 is more susceptible …

This paper aims to observe and analyze the safety and clinical efficacy of Fingolimod
combined with alteplase intravenous thrombolysis in the treatment of acute ischemic stroke …

Background and aim: Disease-modifying therapies (DMTs) used in multiple sclerosis (MS)
have distinct safety profiles. In this paper, we report preliminary results of an on-going …

Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for
management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive …

Purpose We performed a pharmacovigilance study of 10 drugs used in patients with
relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the …

Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central
nervous system, with inflammation and loss of myelin in axons. Fingolimod is the first oral …

The aim: Multiple sclerosis (MS) is a disease of the central nervous system (CNS)
characterized by inflammation and demyelination, which leads to chronic progressive …

Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for
management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive …